摘要
目的分析培美曲塞二钠联合顺铂在晚期肺癌(lung cancer,LC)患者中的应用效果。方法选取2016年6月—2021年6月期间福建医科大学附属三明市第一医院收治的126例晚期LC患者,使用随机数表法为研究组及对照组,各63例。对照组接受吉西他滨联合顺铂治疗,研究组接受培美曲塞二钠联合顺铂治疗。对比两组患者的疗效。结果研究组疾病控制率为88.89%、有效率为69.84%,较对照组的74.60%、52.38%更高,差异有统计学意义(χ^(2)=4.308,4.041,P<0.05)。治疗后,研究组糖类抗原125、细胞角蛋白19片段、癌胚抗原水平均低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论晚期LC患者应用顺铂与培美曲塞二钠治疗可以取得较为理想的效果,有效抑制了肿瘤标志物,安全性尚可。
Objective To analyze the effect of pemetrexed disodium combined with cisplatin in patients with advanced lung cancer(LC).Methods 126 patients with advanced LC admitted to the First Hospital of Sanming City,Fujian Medical University from June 2016 to June 2021 were selected and randomly divided into a study group and a control group using a random number table,with 63 patients in each group.The control group received gemcitabine combined with cisplatin treatment,while the study group received pemetrexed disodium combined with cisplatin treatment.Compared the efficacy of two groups of patients.Results The disease control rate and effective rate of the study group were 88.89%and 69.84%,which were higher than the control group′s 74.60%and 52.38%,the difference was statistically significant(χ^(2)=4.308,4.041,P<0.05).After treatment,the levels of carbohydrate antigen-125,cytokeratin 19 fragment,carcino embryonic antigen in the study group were lower than those in the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of cisplatin and pemetrexed disodium in the treatment of patients with advanced LC can achieve more satisfactory results,effectively inhibit the tumor markers,and the safety is still acceptable.
作者
魏植强
WEI Zhiqiang(Department of Medical Oncology,Sanming First Hospital Affiliated to Fujian Medical University,Sanming,Fujian Province,365000 China)
出处
《中外医疗》
2023年第23期88-91,共4页
China & Foreign Medical Treatment
关键词
培美曲塞二钠
顺铂
晚期
肺癌
Pemetrexed disodium
Cisplatin
Advancer
Lung cancer
